CytomX Therapeutics (CTMX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	41.60 mm	41.60 mm	41.60 mm	41.60 mm		41.60 mm
Cash burn (monthly)	(no burn)	1.40 mm	(no burn)	(no burn)		5.52 mm
Cash used (since last report)	n/a	3.93 mm	n/a	n/a		15.46 mm
Cash remaining	n/a	37.67 mm	n/a	n/a		26.14 mm
Runway (months of cash)	n/a	26.8	n/a	n/a		4.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

CTMX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	77	68	+13.2%
Opened positions	28	55	-49.1%
Closed positions	19	2	+850.0%
Increased positions	21	2	+950.0%
Reduced positions	19	3	+533.3%

13F shares	Current	Prev Q	Change
Total value	58.21 bn	41.10 bn	+41.6%
Total shares	68.99 mm	35.58 mm	+93.9%
Total puts	22.90 k	0.00	NEW
Total calls	22.30 k	49.10 k	-54.6%
Total put/call ratio	1.0	–	–

Largest owners	Shares	Value	Change
Tang Capital Management	7.79 mm	$9.51 bn	NEW
Biotechnology Value Fund L P	6.60 mm	$9.56 mm	0.0%
JHG Janus Henderson	6.30 mm	$7.72 bn	NEW
Cormorant Asset Management	5.75 mm	$25.88 mm	NEW
BVF	5.23 mm	$6.38 bn	NEW
Vanguard	4.89 mm	$5.97 bn	+0.7%
Tang Capital Partners	3.51 mm	$0.00	0.0%
Adage Capital Partners GP, L.L.C.	3.00 mm	$3.66 bn	+50.0%
Acadian Asset Management	2.73 mm	$3.32 mm	+1.4%
Lightstone Ventures II	2.44 mm	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
Tang Capital Management	7.79 mm	+7.79 mm	NEW
JHG Janus Henderson	6.30 mm	+6.30 mm	NEW
Cormorant Asset Management	5.75 mm	+5.75 mm	NEW
BVF	5.23 mm	+5.23 mm	NEW
Millennium Management	1.85 mm	+1.85 mm	NEW
Sio Capital Management	0.00	-1.60 mm	EXIT
Laurion Capital Management	1.53 mm	+1.53 mm	NEW
Jacobs Levy Equity Management	1.51 mm	+1.51 mm	NEW
Schonfeld Strategic Advisors	1.38 mm	+1.38 mm	NEW
RTW Investments	1.20 mm	+1.20 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CTMX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Aug 24	Lloyd A Rowland	Common Stock	Sell	Dispose S	No	No	1.2291	4,181	5.14 k	130,797
20 Aug 24	Lloyd A Rowland	Common Stock	Option exercise	Acquire M	No	No	0	11,250	0.00	134,978
20 Aug 24	Lloyd A Rowland	Performance Stock Units (PSUs) Common Stock	Option exercise	Dispose M	No	No	0	11,250	0.00	0
20 Aug 24	Jeffrey B Landau	Common Stock	Sell	Dispose S	No	No	1.2291	4,181	5.14 k	119,056
20 Aug 24	Jeffrey B Landau	Common Stock	Option exercise	Acquire M	No	No	0	11,250	0.00	123,237
20 Aug 24	Jeffrey B Landau	Performance Stock Units (PSUs) Common Stock	Option exercise	Dispose M	No	No	0	11,250	0.00	0
20 Aug 24	McCarthy Sean A.	Common Stock	Sell	Dispose S	No	No	1.2291	13,898	17.08 k	657,851
20 Aug 24	McCarthy Sean A.	Common Stock	Option exercise	Acquire M	No	No	0	37,500	0.00	671,749
20 Aug 24	McCarthy Sean A.	Performance Stock Units (PSUs) Common Stock	Option exercise	Dispose M	No	No	0	37,500	0.00	0
20 Aug 24	Christopher Ogden	Common Stock	Sell	Dispose S	No	No	1.2291	1,984	2.44 k	108,077

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics

11 Nov 24

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.

12 Health Care Stocks Moving In Friday's Pre-Market Session

8 Nov 24

12 Health Care Stocks Moving In Friday's Pre-Market Session

8 Nov 24

12 Health Care Stocks Moving In Friday's Pre-Market Session

8 Nov 24

CytomX Therapeutics Q3 2024 GAAP EPS $0.07 Beats $(0.17) Estimate, Sales $33.432M Beat $17.514M Estimate

7 Nov 24